Q4: 2026-02-11 Earnings Summary
EPS of -$1.38 misses by $0.48
| Revenue of $0.00 beats by $0.00
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call February 11, 2026 4:30 PM EST
Company Participants
Brian Lian – President, CEO & Director
Gregory Zante – Chief Financial Officer
Neil Aubuchon – Chief Commercial Officer
Conference Call Participants
Stephanie Diaz – Vida Strategic Partners, Inc.
Timur Ivannikov – Cantor Fitzgerald & Co., Research Division
Joon Lee – Truist Securities, Inc., Research Division
Hardik Parikh – JPMorgan Chase & Co, Research Division
Tsan-Yu Hsieh – William Blair & Company L.L.C., Research Division
William Wood – B. Riley Securities, Inc., Research Division
Jiale Song – Jefferies LLC, Research Division
Annabel Samimy – Stifel, Nicolaus & Company, Incorporated, Research Division
Biren Amin – Piper Sandler & Co., Research Division
Rohit Bhasin – Morgan Stanley, Research Division
Thomas Smith – Leerink Partners LLC, Research Division
Yale Jen – Laidlaw & Company (UK) Ltd., Research Division
Ryan Deschner – Raymond James & Associates, Inc., Research Division
Presentation
Operator
Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 11, 2026.
I would now like to turn the call over to Viking’s Manager of Investor Relations, Ms. Stephanie Diaz. Please go ahead, Stephanie.
Stephanie Diaz
Vida Strategic Partners, Inc.
Hello, and thank you all for participating in today’s call. Joining me today is Brian Lian, Viking’s President and CEO; and Greg Zante, Viking’s CFO.
Before we begin, I’d like to caution that comments made during this conference call today, February 11, 2026, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking’s expectations regarding its development activities, time lines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance.